MAS Receptor Agonists for Mitophagy and Mitochondrial Turnover

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective solutions for stimulating mitochondrial turnover, which is essential for treating diseases associated with mitochondrial dysfunction.

Innovation Solution

Administering a mitophagy-stimulating amount of a MAS receptor agonist or a substance that triggers endogenous production of a MAS receptor agonist to stimulate mitophagy pathways, promoting mitochondrial biogenesis, autophagosome formation, and degradation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional methods are used to treat mitochondrial dysfunction, then disease management is attempted, but effective stimulation of mitochondrial turnover is not achieved

Engineering Contradiction:

Improveeffectiveness of mitochondrial turnover stimulationVSAvoidavailability of therapeutic options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the biochemical parameter by introducing MAS receptor agonists that activate specific signaling pathways (mTORC1, NRF2, TFEB) to stimulate mitophagy. This parameter change transforms the therapeutic approach from conventional mitochondrial support to active turnover stimulation, achieving reliable enhancement of mitochondrial renewal processes.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses MAS receptor agonists as intermediary substances that mediate between external administration and internal mitochondrial turnover processes. These agonists act as mediators that trigger endogenous mitophagy pathways through receptor activation, providing an effective bridge between therapeutic intervention and cellular response.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If mitochondrial turnover is stimulated using existing approaches, then some therapeutic benefit may be obtained, but the mechanisms are not well understood and effectiveness is limited

Engineering Contradiction:

Improverate of mitochondrial turnoverVSAvoidcomplexity of therapeutic mechanism

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the mitochondrial turnover process into distinct mechanistic pathways (mTORC1 activation, NRF2 activation, TFEB expression, inhibition of ATP hydrolysis by Complex V, mitochondrial dynamics). By targeting specific segments of the turnover process through MAS receptor agonists, the patent achieves enhanced productivity while maintaining manageable mechanistic complexity through focused pathway activation.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12343331B2Methods and agents that stimulate mitochondrial turnover for treating disease

Publication Date: 2025.07.01 CAPACITY BIO INC

AI summary

Provided herein are methods of stimulating mitophagy in a subject in need thereof administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist. The present disclosure also relates to medical intervention methods and agents, namely methods and agents for stimulation of mitochondrial turnover for treatment of disease in a mammal. The disclosure comprises a method of stimulating increased mitochondrial turnover in a mammal comprising administering to the mammal a pharmacologically suitable dose of a MAS receptor agonist; MAS receptor modulator; a substance that triggers endogenous production of a MAS receptor agonist; a substance that triggers endogenous production of a MAS receptor modulator; or any combination thereof. The pharmacological activity acting on MAS receptor in turn stimulates an increase in mitochondrial turnover in host cells, alleviating a disease state in the host mammalian organism.